Artivion Exercises Option to Acquire Endospan

May 8, 2026—Artivion, Inc., headquartered in suburban Atlanta, Georgia, will acquire Israel-based Endospan, a developer of solutions for the endovascular repair of aortic arch disease.

In a press release reporting the company’s Q1 2026 financial results, Pat Mackin, who is Chairman, President, and Chief Executive Officer of Artivion, announced that Artivion had exercised its option to acquire Endospan for an upfront purchase price of $135 million, net of previously extended loans. He advised that the acquisition was expected to close in the second quarter of 2026, subject to customary closing conditions.

Mackin noted that Endospan’s Nexus aortic arch stent graft had received FDA premarket approval for the treatment of aortic arch disease, including chronic aortic dissections. Endospan recently announced the FDA approval, which was supported by the 1-year results of the prospective multicenter TRIOMPHE investigational device exemption study.

In 2019, Artivion (formerly known as CryoLife, Inc.) announced it had entered into distribution and credit facility agreements with Endospan and advised it had an option agreement to purchase Endospan. In July 2024, Endospan announced an agreement with Artivion to receive additional loans of up to $25 million to be used to pursue FDA approval of the Nexus device.